ClinicalTrials.gg
CompletedNCT05237921CEDIUpdated Mar 19, 2024

Adherence to Exercise and Dietary Intervention in Cancer Patients

An interventional study of Combined Exercise and Dietary Intervention (CEDI) and Standard Care in Adherence and Gastrointestinal Cancer, sponsored by Hospital Beatriz Ângelo. Completed at 1 site in Portugal. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Hospital Beatriz Ângelo · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Jun 2018, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Intervention programs in cancer patients have been proposed with the aim of improving outcome. Bearing in mind that compliance is a limiting factor to the benefit provided from exercise and diet, assessing adherence to these interventions is paramount before pursuing further studies. Therefore the purpose of this study was to study the adherence of gastrointestinal cancer patients to a Combined Exercise and Dietary Intervention (CEDI) during neo-adjuvant chemotherapy.

02

Conditions studied

  • Adherence
  • Gastrointestinal Cancer

Keywords

  • Body composition
  • Wasting
  • Malnutrition
03

In context

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

This study's enrollment of 50 is below the median of 73 across 497 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

Hospital Beatriz Ângelo is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with esophageal, gastric, pancreatic and rectal cancer
  • Due to commence chemo/ radiotherapy (ChT)

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Combined Exercise and Dietary Intervention

    Behavioral Intervention

    Behavioral: Combined Exercise and Dietary Intervention (CEDI)

  • Other
    Control

    Standard Care

    Behavioral: Standard Care

Interventions

  • BehavioralCombined Exercise and Dietary Intervention (CEDI)

    Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status. Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake.

  • BehavioralStandard Care

    Standard Care

06

What researchers measure

Primary outcomes

  1. Number of participants that adhere to a Combined Exercise and Dietary Intervention (CEDI)

    The aim of this study was to assess intervention adherence defined as the number of participants willing to engage in CEDI.

    Time frame: 8 weeks

Secondary outcomes

  1. Number of participants that meet estimated dietary intake and exercise goals

    We will assess the number of participants able to achieve their estimated dietary goals, namely 25-30kcal/day and 1-1.5g protein day and at least attending to 50% of planed exercise sessions.

    Time frame: 8 weeks

07

Study locations

1 site
  • Hospital Beatriz Ângelo
    Loures, Lisboa 2674-514, Portugal
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study protocol with statistical analysis plan will be uploaded to trials.gov.

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jun 2022, 48 months.

Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 48 months is above that.

Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Feb 14, 2022
StartActual
Jun 15, 2018
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05237921
Lead sponsor
Hospital Beatriz Ângelo
Responsible party
Sónia Velho (Nutricionist, Hospital Beatriz Ângelo) — Principal investigator
First posted
Feb 14, 2022
Start date
Jun 15, 2018
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Mar 19, 2024

Study contacts

Cravo
study director · Hospital da Luz

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion